Advertisement
Advertisement

OVID

OVID logo

Ovid Therapeutics Inc. Common Stock

1.56
USD
Sponsored
+0.01
+0.65%
Jan 30, 16:00 UTC -5
Closed
exchange

Pre-Market

1.56

0.00
0.00%

OVID Earnings Reports

Positive Surprise Ratio

OVID beat 20 of 35 last estimates.

57%

Next Report

Date of Next Report
Mar 09, 2026
Estimate for Q4 25 (Revenue/ EPS)
$13.60K
/
-$0.12
Implied change from Q3 25 (Revenue/ EPS)
-89.70%
/
-29.41%
Implied change from Q4 24 (Revenue/ EPS)
-82.11%
/
-7.69%

Ovid Therapeutics Inc. Common Stock earnings per share and revenue

On Nov 12, 2025, OVID reported earnings of -0.17 USD per share (EPS) for Q3 25, missing the estimate of -0.15 USD, resulting in a -11.18% surprise. Revenue reached 132.00 thousand, compared to an expected 134.06 thousand, with a -1.54% difference. The market reacted with a -2.22% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 13.60 thousand USD, implying an decrease of -29.41% EPS, and decrease of -89.70% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Ovid Therapeutics Inc. Common Stock reported EPS of -$0.17, missing estimates by -11.18%, and revenue of $132.00K, -1.54% below expectations.
The stock price moved down -2.22%, changed from $1.35 before the earnings release to $1.32 the day after.
The next earning report is scheduled for Mar 09, 2026.
Based on 12 analysts, Ovid Therapeutics Inc. Common Stock is expected to report EPS of -$0.12 and revenue of $13.60K for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement